Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (111-120 of 350) with videos related to

Pageof 35
Sort By:
Journal of Crohn'S & Colitis|January 20, 2023
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel DiseasesWannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, et al.
The Journal of Pediatrics|September 5, 2021
Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination TherapyKaren van Hoeve, Nasim Sadat Seyed Tabib, Erwin Dreesen, et al.
Journal of Crohn'S & Colitis|June 19, 2026
Gastrointestinal symptom-specific anxiety is associated with disability in inflammatory bowel diseases independent of general anxiety and self-reported disease activity: evidence from a large cross-sectional patient studySarah Van den Borren, Livia Guadagnoli, Anouk Teugels, et al.
European Journal of Gastroenterology & Hepatology|February 21, 2018
The operative risk and natural history after the diagnosis of ileal penetrating Crohn's diseasePeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
Cells|August 1, 2020
Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative ColitisHo-Su Lee, Maaike Vancamelbeke, Sare Verstockt, et al.
European Journal of Gastroenterology & Hepatology|March 7, 2019
Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decadesAnnick Moens, Bram Verstockt, Kathleen Machiels, et al.
Inflammatory Bowel Diseases|August 11, 2019
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral CenterMichiel Bronswijk, Annick Moens, Matthias Lenfant, et al.
Journal of Crohn'S & Colitis|March 29, 2019
Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative ColitisMaaike Vancamelbeke, Thessa Laeremans, Wiebe Vanhove, et al.
European Journal of Gastroenterology & Hepatology|June 25, 2024
Development of a set of measurable outcome indicators for Flemish patients with inflammatory bowel diseaseLiselotte Fierens, Peter Bossuyt, Filip Baert, et al.
Journal of Clinical Gastroenterology|February 23, 2026
Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease: Results From the EVOLVE Expansion Chart Review StudyMarc Ferrante, Britt Christensen, Brian Bressler, et al.
Pageof 35

Showing results (111-120 of 350) with videos related to

Sort By:
Pageof 35
Journal of Crohn'S & Colitis|January 20, 2023
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel DiseasesWannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, et al.
The Journal of Pediatrics|September 5, 2021
Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination TherapyKaren van Hoeve, Nasim Sadat Seyed Tabib, Erwin Dreesen, et al.
Journal of Crohn'S & Colitis|June 19, 2026
Gastrointestinal symptom-specific anxiety is associated with disability in inflammatory bowel diseases independent of general anxiety and self-reported disease activity: evidence from a large cross-sectional patient studySarah Van den Borren, Livia Guadagnoli, Anouk Teugels, et al.
European Journal of Gastroenterology & Hepatology|February 21, 2018
The operative risk and natural history after the diagnosis of ileal penetrating Crohn's diseasePeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
Cells|August 1, 2020
Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative ColitisHo-Su Lee, Maaike Vancamelbeke, Sare Verstockt, et al.
European Journal of Gastroenterology & Hepatology|March 7, 2019
Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decadesAnnick Moens, Bram Verstockt, Kathleen Machiels, et al.
Inflammatory Bowel Diseases|August 11, 2019
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral CenterMichiel Bronswijk, Annick Moens, Matthias Lenfant, et al.
Journal of Crohn'S & Colitis|March 29, 2019
Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative ColitisMaaike Vancamelbeke, Thessa Laeremans, Wiebe Vanhove, et al.
European Journal of Gastroenterology & Hepatology|June 25, 2024
Development of a set of measurable outcome indicators for Flemish patients with inflammatory bowel diseaseLiselotte Fierens, Peter Bossuyt, Filip Baert, et al.
Journal of Clinical Gastroenterology|February 23, 2026
Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease: Results From the EVOLVE Expansion Chart Review StudyMarc Ferrante, Britt Christensen, Brian Bressler, et al.
Pageof 35